Tofacitinib Uptake by Patient-Derived Intestinal Organoids Predicts Individual Clinical Responsiveness-Reference-Cited by-同舟云学术

Tofacitinib Uptake by Patient-Derived Intestinal Organoids Predicts Individual Clinical Responsiveness

Published:2024-07 Issue: Volume: Page:
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Jang Kyung Ku,Hudesman David,Jones Drew R.,Loke P’ng,Axelrad Jordan E.,Cadwell Ken,Ercelen Defne,Cen Feng Jing Yu Carolina,Gurunathan Sakteesh,Newell Luke,Zhou Chaoting,Korman Aryeh

Funder

Howard Hughes Medical Institute

Yonsei University College of Medicine

National Heart, Lung, and Blood Institute

NIDDK

Pfizer

Yonsei University College of Dentistry

Crohn's and Colitis Foundation

National Institute of Allergy and Infectious Diseases Division of Intramural Research

Janssen Scientific Affairs

Nihon Superior

Jordan Brungardt

National Health Research Institutes

Pfizer Foundation

National Cancer Institute

National Institute of Allergy and Infectious Diseases

Kenneth Rainin Foundation

Crohn's and Colitis Foundation of America

Publisher

Elsevier BV

Reference21 articles.

1. Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis

2. An intestinal organoid–based platform that recreates susceptibility to T-cell–mediated tissue injury

3. TNF-α synergises with IFN-γ to induce caspase-8-JAK1/2-STAT1-dependent death of intestinal epithelial cells

4. DNA sensor-associated type I interferon signaling is increased in ulcerative colitis and induces JAK-dependent inflammatory cell death in colonic organoids

5. Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discordant Effects of Janus Kinase Inhibition Ex Vivo on Inflammatory Responses in Colonic Compared to Ileal Mucosa;Journal of Crohn's and Colitis;2024-07-29